Sentimag - Magseed in breast cancer

Due to improvements in screening and patient awareness, approximately 50% of breast lesions are impalpable at the time of diagnosis. The current gold standard to assist the surgeon in finding an impalpable lesion is a hookwire, or guidewire. These are usually placed on the morning of surgery. Wire-guided localisations (WGL) have been used since the 1960s and have several limitations, including migration of the wire, scheduling conflicts and patient dissatisfaction.

Magseed^® has been specifically developed to overcome these issues. It promotes seamless operating room (OR) scheduling, accurate lesion localisation and patient satisfaction.

Our system consists of the Sentimag^® probe and the Magseed^® magnetic marker. First, the marker is placed under ultrasound or X-ray guidance up to 30 days before surgery. In the OR, the surgeon uses Sentimag^® to precisely localise Magseed^® and therefore the lesion.

Magseed – Benefits for all

• Organise the lesion localisation procedure to suit your needs
• Can be placed 30 days in advance – better for patients, better for the clinical workflow
• Greatly improved OR and radiology scheduling
• 360-degree sensing and distance calculation for the best oncoplastic approach
• Patient-centric approach: no radioactivity, reduced stress, minimal invasiveness
• Sentimag^® and Magseed^® are FDA-cleared and CE-marked for lesion localisation

Endomag^®, Sentimag^® and Magseed^® are registered European Union trademarks of Endomagnetics Ltd <link http: www.endomag.com external-link-new-window external link in new>www.endomag.com

Magtrace^® is a registered trademark of Endomagnetics Ltd in the United Kingdom <link http: www.endomag.com external-link-new-window external link in new>www.endomag.com